Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

DOI Full Paper Access

169

Citations

25

References

2021

Year

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar, Volker Straub, António Toscano, Ans T. van der Ploeg, Kenneth I. Berger, Paula R. Clemens,

The Lancet Neurology

Late-onset Pompe DiseaseAutoimmune DiseaseClinical Infectious DiseaseMedicinePhase 3Avalglucosidase Alfa

References

	Year	Citations

Page 1